<?xml version="1.0" encoding="UTF-8"?>
<p>The antiviral activity of chloroquine was already identified in the late 1960s.
 <sup>
  <xref rid="bibr5-2048872620922790" ref-type="bibr">5</xref>
 </sup> Both chloroquine and hydroxychloroquine are able to inhibit a broad range of viruses from different virus families in cell culture, including coronaviruses (SARS-CoV-1, MERS-CoV).
 <sup>
  <xref rid="bibr6-2048872620922790" ref-type="bibr">6</xref>,
  <xref rid="bibr7-2048872620922790" ref-type="bibr">7</xref>
 </sup> Recently, in vitro antiviral efficacy against SARS-CoV-2 was also demonstrated.
 <sup>
  <xref rid="bibr8-2048872620922790" ref-type="bibr">8</xref>
 </sup> For some viruses, antiviral activity was observed in mouse models, including for the human coronavirus OC43
 <sup>
  <xref rid="bibr9-2048872620922790" ref-type="bibr">9</xref>
 </sup> and influenza A virus H5N1.
 <sup>
  <xref rid="bibr10-2048872620922790" ref-type="bibr">10</xref>
 </sup> However, in a SARS-CoV-1 mouse model, chloroquine was not able to reduce viral titres in the lungs.
 <sup>
  <xref rid="bibr11-2048872620922790" ref-type="bibr">11</xref>
 </sup> In patients, no evidence of antiviral activity has yet been observed during acute viral infections.
 <sup>
  <xref rid="bibr5-2048872620922790" ref-type="bibr">5</xref>
 </sup>
</p>
